ACTRIMS Investor Call

Sanofi was pleased to invite investors and analysts to participate in a live webcast discussing tolebrutinib data presented during the ACTRIMS scientific program (February 24-26, 2022).

(16h00 CET / 10:00am EST)


Dietmar Berger

Global Head of Development,

Tom Snow

Global Franchise Head, Neurology

Erik Wallstroem

Therapeutic Area Head, Multiple Sclerosis

Anthony Traboulsee

Professor and Research Chair of the MS Society of Canada at the University of British

Tim Turner

Global Project Head, Neurology



Tolebrutinib_Outcomes of COVID-19 Cases from LTE Study in MS

Tolebrutinib_18-month Results from the LTE Study in MS

Tolebrutinib_Comparative CNS Pharmacology